Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 1/2010

01-02-2010 | Clinical Trial

Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature

Authors: Youlia M. Kirova, Alexia Savignoni, Brigitte Sigal-Zafrani, Anne de La Rochefordiere, Rémy J. Salmon, Pascale This, Bernard Asselain, Dominique Stoppa-Lyonnet, Alain Fourquet

Published in: Breast Cancer Research and Treatment | Issue 1/2010

Login to get access

Abstract

As tumours in BRCA1/2 mutation carriers might be more sensitive to radiation, we investigated after long-term follow-up whether mutation status influenced the rate of ipsilateral and contralateral breast cancers after breast-conserving treatment (BCT). BRCA1 and BRCA2 genes were screened for germline mutations in 131 patients with a family history of breast and/or ovarian cancer who had undergone BCT and radiotherapy. Patients were matched to 261 controls with sporadic breast cancer according to age at diagnosis and year of treatment. Controls were followed up for at least as long as the interval between diagnosis and genetic screening in familial cases. Rates of ipsilateral and contralateral cancer between groups were compared by the log-rank test. The BRCA1/2 mutations occurred in 20.6% of tested patients. Tumours in mutation carriers were more likely to be grade III (P < 10−4) and oestrogen receptor negative (P = 0.005) than in non-carriers and controls. Overall median follow-up was 161 months. There was no significant difference in ipsilateral tumours between mutation carriers, non-carriers and controls (P = 0.13). On multivariate analysis, age was the most significant predictor for ipsilateral recurrence (P < 10−3). The rate of contralateral cancer was significantly higher in familial cases: 40.7% (mutation carriers), 20% (non-carriers), and 11% (controls) (P < 10−4). After 13.4 years of follow-up, the rate of ipsilateral tumours was no higher in mutation carriers than in non-carriers or controls. As tumours in BRCA1/2 mutation carriers might be more sensitive to radiation, BCT is a possible treatment option.
Literature
1.
Robson ME (2002) Clinical considerations in the management of individuals at risk for hereditary breast and ovarian cancer. Cancer Control 9:457–465PubMed
2.
Adem C, Reynolds C, Soderberg CL et al (2003) Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers. Cancer 97:1–11CrossRefPubMed
3.
Chappuis PO, Nethercot V, Foules WD et al (2000) Clinico-pathological characteristics of BRCA1 and BRCA2-related breast cancer. Semin Surg Oncol 18:287–295CrossRefPubMed
4.
Stoppa-Lyonnet D, Ansquer Y, Dreyfus H et al (2000) Familial invasive breast cancers: worse outcome related to BRCA1 mutations. J Clin Oncol 18:4053–4059PubMed
5.
Foulkes WD, Chappuis PO, Wong N et al (2000) Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome. Ann Oncol 11:307–313CrossRefPubMed
6.
Verhoog LC, Brekelmans CTM, Seynaeve C et al (1998) Survival and tumour characteristics of breast cancer patients with germline mutations of BRCA1. Lancet 351:316–321CrossRefPubMed
7.
Breast Cancer Linkage Consortium (1997) Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet 349:1505–1510CrossRef
8.
Lakhani SR, Jacquemier J, Sloane JP et al (1998) Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 90:1138–1145CrossRefPubMed
9.
Robson M, Chappuis PO, Satagopan J et al (2004) A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res 6:R8–R17CrossRefPubMed
10.
Venkitaraman A (2002) Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 108:171–182CrossRefPubMed
11.
Powel SN, Kachnic LA (2003) Roles of BRCA1 and BRCA2 in homologous recombination, DNA replication fidelity and the cellular response to ionising radiation. Oncogene 22:5784–5791CrossRef
12.
Baeyens A, Thierens H, Claes K et al (2002) Chromosomal radiosensitivity in breast cancer patients with a known or putative genetic predisposition. Br J Cancer 87:1379–1385CrossRefPubMed
13.
Freneaux P, Stoppa-Lyonnet D, Mouret E et al (2000) Low expression of bcl-2 in Brca1-associated breast cancers. Br J Cancer 83:1318–1322CrossRefPubMed
14.
Hedenfalk I, Duggan D, Chen Y et al (2001) Gene-expression profiles in hereditary breast cancer. N Engl J Med 344:539–548CrossRefPubMed
15.
Cortez D, Wang Y, Qin J et al (1999) Requirement of ATM-dependent phosphorylation of Brca1 in the DNA damage response to double-strand breaks. Science 286:1162–1166CrossRefPubMed
16.
Scully R, Chen J, Ochs RL et al (1997) Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage. Cell 90:425–435CrossRefPubMed
17.
Xu X, Weaver Z, Linke SP et al (1999) Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. Mol Cell 3:389–395CrossRefPubMed
18.
Brodie SG, Xu X, Qiao W et al (2000) Multiple genetic changes are associated with mammary tumorigenesis in BRCA1 conditional knockout mice. Oncogene 20:7514–7523CrossRef
19.
Fourquet A, Stoppa-Lyonnet D, Sigal-Zafrani B et al (2009) Familial invasive breast cancer: clinical response to induction chemotherapy or radiotherapy related to BRCA1 and BRCA2 mutations. Am J Clin Oncol 32:127–131CrossRefPubMed
20.
Fisher B, Anderson S, Bryant J et al (2002) Twenty-year follow-up of a randomised trial comparing total mastectomy, lumpectomy and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 347:1233–1241CrossRefPubMed
21.
Clark R, McCullock P, Levine M et al (1992) Randomised clinical trial to assess the effectiveness of breast irradiation following lumpectomy and axillary dissection for node-negative breast cancer. J Natl Cancer Inst 84:683–689CrossRefPubMed
22.
Van Dongen JA, Voogd AC, Fentiman IS et al (2000) Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: EORTC 10801 trial. J Natl Cancer Inst 92:1143–1150CrossRefPubMed
23.
Veronesi U, Cascinelli N, Mariani L et al (2002) Twenty-year follow-up of a randomised study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 347:1227–1232CrossRefPubMed
24.
Jacobson JA, Danforth DN, Cowan KH et al (1995) Ten-year results of a comparison of conservation with mastectomy in the treatment of stage I and II breast cancer. N Engl J Med 332:907–911CrossRefPubMed
25.
Blichert-Toft M, Roce C, Anderson JA et al (1992) Danish randomised trial comparing breast conservation therapy with mastectomy: six years of life table analysis. Danish Breast Cancer Cooperative group. J Natl Cancer Inst Monograms 11:19–25
26.
Arriagada R, Le MG, Guinebretière JM et al (2003) Late local recurrences in a randomised trial comparing conservative treatment with total mastectomy in early breast cancer patients. Ann Oncol 14:1617–1622CrossRefPubMed
27.
Early Breast Cancer Trialists’ Collaborative Group (2005) Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366:2087–2106
28.
Kirova YM, Stoppa-Lyonnet D, Savignoni A et al (2005) Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy. Eur J Cancer 41:2304–2311CrossRefPubMed
29.
Pierce LJ, Strawderman M, Narod SA et al (2000) Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations. J Clin Oncol 18:3360–3369PubMed
30.
Pierce L, Levin A, Rebbeck T et al (2006) Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol 24:2437–2443CrossRefPubMed
31.
Brekelmans CT, Tilanus-Linthorst MM, Seynaeve C et al (2007) Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases. Eur J Cancer 43(5):867–876CrossRefPubMed
32.
Delaloge S, Kloos I, Ariane D et al (2003) Young age is the major predictor of local relapse among conservatively treated BRCA1-, BRCA2-, or non BRCA-linked hereditary breast cancer. ASCO Proc 22(abstr 41):11
33.
Kirova YM, De Rycke Y, Gambotti L et al (2008) Second malignancies after breast cancer: the impact of different treatment modalities. Br J Cancer 98:870–874CrossRefPubMed
34.
Kirova Y, Vilcoq JR, Asselain B et al (2005) Radiation-induced sarcomas (RIS) following radiotherapy for breast cancer: a large-scale single institution review. Cancer 104:856–863CrossRefPubMed
35.
Thompson D, Easton DF (2002) The breast cancer linkage consortium: cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst 94:1358–1365PubMed
36.
Kirova YM, Fourquet A, Savignoni A et al (2006) Risk of second non breast malignancies (SNBM) in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy. Am J Immunol 2:61–63CrossRef
37.
Haffty BG, Harrold E, Khan AJ et al (2002) Outcome of conservatively managed early-onset breast cancer by BRCA1/BRCA2 status. Lancet 359:1471–1477CrossRefPubMed
38.
Seynaeve C, Verhoog LC, Van De Bosch LM et al (2004) Ipsilateral breast tumour recurrence in hereditary breast cancer following breast-conserving therapy. Eur J Cancer 40:1150–1158CrossRefPubMed
39.
Bremer M, Doerk T, Sohn C et al (2003): Local relapse after postoperative radiotherapy in patients with bilateral breast cancer by BRCA1/2 status. ASCO Proc 22(abstr 42):11
40.
Turner BC, Harrold E, Matloff E et al (1999) BRCA1/BRCA2 germline mutations in locally recurrent breast cancer patients after lumpectomy and radiation therapy: implications for breast-conserving management in patients with BRCA1/BRCA2 mutations. J Clin Oncol 17:3017–3024PubMed
41.
Garcia-Etienne CA, Barile M, Gentilini OD et al (2009) Breast-conserving surgery in BRCA1/2 mutation carriers: are we approaching an answer? Ann Surg Oncol (in press)
42.
Stoppa-Lyonnet D, Laurent-Puig P, Essioux L et al (1997) BRCA1 sequence variations in 160 individuals referred to a breast/ovarian family cancer clinic. Institut Curie Breast Cancer Group. Am J Hum Genet 60:1021–1030PubMed
43.
Wagner T, Stoppa-Lyonnet D, Fleischmann E et al (1999) Denaturing high-performance liquid chromatography detects reliably BRCA1 and BRCA2 mutations. Genomics 62:369–376CrossRefPubMed
44.
Claus EB, Risch N, Thompson WD (1991) Genetic analysis of breast cancer in the cancer and steroid hormone study. Am J Hum Genet 48:232–242PubMed
45.
Easton DF, Bishop DT, Ford D et al (1993) Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. Am J Hum Genet 52:678–701PubMed
46.
Salmon RJ, Asselain B, Le Gal M et al (1997) Twelve years experience of breast cancer at the Institut Curie: improvement of survival and value of screening mammographics. Breast 6:202–205CrossRef
47.
Kirova Y, Servois V, Campana F et al (2006) CT- scan based localization of the internal mammary chain and supra clavicular nodes for breast cancer radiation therapy planning. Radiother Oncol 79:310–315CrossRefPubMed
48.
Campana F, Kirova YM, Rosenwald JC et al (2005) Breast radiotherapy in the lateral decubitus position–a technique to prevent lung and heart irradiation. Int J Radiat Oncol Biol Phys 61:1348–1354PubMed
49.
Kirova YM, Fournier-Bidoz N, Servois V et al (2008) How to boost the breast tumor bed? A multidisciplinary approach in 8 steps. Int J Radiat Oncol Biol Phys 72:494–500PubMed
50.
Kaplan EL, Meier P (1958) Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457–481CrossRef
51.
Mantel N (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163–170PubMed
52.
Cox DR (1972) Regression models and life tables. J R Stat Soc 34:187–220
53.
Narod SA, Brunet JS, Ghadirian P et al (2000) Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case–control study. Lancet 356:1876–1881CrossRefPubMed
54.
Pierce L (2002) Radiotherapy for breast cancer in BRCA1/BRCA2 carriers: clinical issues and management dilemmas. Semin Radiat Oncol 12:352–361CrossRefPubMed
55.
Meijers-Heijboer EJ, Verhoog LC, Brekelmans CTM et al (2000) Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation. Lancet 355:2015–2020CrossRefPubMed
56.
Reicht A (2009) Contralateral prophylactic mastectomy: caveat emptor. J Clin Oncol 27:1347–1349CrossRef
57.
Drew Y, Calvert H (2008) The potential of PARP inhibitors in genetic breast and ovarian cancers. Ann N Y Acad Sci 1138:136–145CrossRefPubMed
Metadata
Title
Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature
Authors
Youlia M. Kirova
Alexia Savignoni
Brigitte Sigal-Zafrani
Anne de La Rochefordiere
Rémy J. Salmon
Pascale This
Bernard Asselain
Dominique Stoppa-Lyonnet
Alain Fourquet
Publication date
01-02-2010
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2010
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-009-0685-6

Other articles of this Issue 1/2010

Breast Cancer Research and Treatment 1/2010 Go to the issue

Review

Impact of breast surgery on survival in patients with distant metastases at initial presentation: a systematic review of the literature

Letter to the editor

Additive effects of genetic variations of xenobiotic detoxification enzymes and DNA repair gene XRCC1 on the susceptibility to breast cancer

Epidemiology

No evidence that social stress is associated with breast cancer incidence

Preclinical study

Effects of autotransplanted lymph node fragments on the lymphatic system in the pig model

Epidemiology

Low level alcohol intake, cigarette smoking and risk of breast cancer in Asian-American women

Letter to the editor

Eligible and not eligible studies in the recent meta-analysis about p53 polymorphism and breast cancer risk
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits